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Abstract 
 
Nrf2 is a basic leucine zipper transcriptional activator that is essential for the 
coordinate transcriptional induction of various antioxidant drug metabolizing 
enzymes. Numerous studies have firmly established Nrf2’s importance in the 
protection from oxidative stress and certain chemical insults. Given the 
protective function of Nrf2, surprisingly few studies have focused on the 
relationship between Nrf2 and apoptosis. Therefore, we analyzed how Nrf2 
influences Fas signaling using Nrf2 deficient T cells. At a concentration of 1 
μg/ml, anti-Fas antibody induced 60% of cell death in Nrf2 deficient cultured 
thymocytes while, using the same treatment, only 40% of Nrf2 wild type 
thymocytes died (P <0.05). Nrf2 deficiency enhances the sensitivity of 
Fas-mediated apoptosis in T cells. Next we examined the effect of Nrf2 
deficiency during hepatocellular apoptosis in vivo. In comparison to wild-type 
mice, Nrf2 deficient mice displayed more severe hepatitis after induction with 
anti-Fas antibody or TNF-α. The enhanced sensitivity to anti-Fas or TNF-α 
stimulation was restored by pre-administration of glutathione ethyl monoester, 
a compound capable of passing the cell membrane and up-regulating the 
intra-cellular levels of glutathione. The results indicated that Nrf2 activity 
regulates the sensitivity of death signals by means of intracellular glutathione 
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levels. 
Nrf2 (NF-E2 related factor 2) was originally defined as a basic leucine 
zipper (b-Zip) transcriptional activator which recognizes the NF-E2 (nuclear 
factor erythroid 2) binding site (Moi et al., 1994; Itoh et al., 1995). Nrf2 is 
essential for the coordinate transcriptional induction of various antioxidant and 
phase II drug metabolizing enzymes through the antioxidant response 
element/electrophile response element (ARE/EpRE) (Itoh et al., 1997; Itoh et al., 
1999). ARE/EpRE sequences have been characterized within the proximal 
regulatory sequences of genes encoding the antioxidant enzymes glutathione 
S-transferase (GST) (Rushmore et al., 1990), NAD(P)H quinone oxidoreductase 
(NQO1) (Favreau et al., 1991), heme oxygenase-1 (HO-1) (Prestera et al., 1995), 
γ-glutamylcysteine synthetase (Chan and Kwong, 2000) and cystine membrane 
transporter (system Xc-) (Ishii et al., 2000). The ARE also regulates a wide range 
of metabolic responses to oxidative stress caused by reactive oxygen species 
(ROS) or electrophiles (Ishii et al., 2000). As a consequence of inadequate 
induction of these molecules, Nrf2 deficient mice are sensitive to high oxidative 
stress and drug-induced stress (Ishii et al., 2000; Cho et al., 2002; Enomoto et al., 
2001). 
       Glutathione (L-γ-glutamyl-cysteinyl-glycine, GSH) is a tripeptide, 
intracellular, non-protein thiol that has a central role in sulfhydryl homeostasis. 
GSH serves as the major cytosolic antioxidant and defends against xenobiotics 
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by acting as a substrate during phase II conjugation reactions (Jones et al., 1986; 
Meister, 1992). Numerous cellular functions are modulated by the glutathione 
disulfide system including, regulation of enzymes vital to metabolism, cell 
growth, gene transcription, and apoptosis (Droge et al., 1994; Uhlig and Wendel 
1992; Hall, 1999). Therefore, cells tightly regulate the synthesis, utilization, and 
export of GSH. The intracellular concentration of GSH is maintained within the 
millimolar range under normal conditions (Anderson, 1997). Synthesis of GSH 
is achieved by the consecutive action of the ATP-dependent enzymes, 
 γ−glutamylcysteine synthetase and glutathione synthetase.  It was reported 
that levels of both these key enzymes are affected by the activity of Nrf2 (Chan 
and Kwong, 2000). In addition, the expression of system Xc- is controlled by 
Nrf2 (Ishii et al., 2000). System Xc- regulates the concentration of intracellular 
cystine, a component substrate for GSH synthesis. Based upon these findings, 
Nrf2 is thought to be one of the main regulators of intracellular GSH levels. 
The cytokine receptor Fas (APO-1/CD95) belongs to the tumor necrosis 
factor (TNF)/nerve growth factor receptor superfamily. Certain members of 
this family, including Fas, are referred to as death receptors since they share a 
cytoplasmic death domain involved in apoptotic signaling (Schulze-Osthoff et 
al., 1998). Fas is expressed by lymphoid and nonlymphoid cells and is regarded 
as a principal trigger for apoptotic cell death of lymphoid cells and hepatocytes 
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(Galle et al., 1995; Nagata, 1997). In both human and murine liver, Fas and TNF- 
receptor I (TNF-RI) can independently trigger apoptosis. Indeed, the 
administration of an activating anti-Fas antibody to mice leads to lethal liver 
destruction within hours due to extensive apoptosis of hepatocytes (Ogasawara 
et al., 1993; Leist et al., 1996). Upon ligand binding and trimerization of Fas, the 
intracellular death domain of the receptor associates with several proteins 
forming a death-inducing signaling complex (DISC) through which the 
recruitment and activation of caspase-8 is initiated (Medema et al., 1997; 
Schulze-Osthoff et al., 1998). This event, in turn, triggers a cascade of proteolytic 
interconversions of procaspases, including downstream caspases such as 
caspase-3 and –7, which finally execute the proteolytic cleavage of various 
structural and signal proteins (Zhivotovsky et al., 1997; Thronberry and 
Lazebnik, 1998; Hirata et al., 1998; Widmann et al.,1998). The ultimate outcome 
of this cascade is apoptosis. TNF-α also plays an integral role in the injury and 
cell death that occurs in hepatocytes following toxin-induced liver damage. 
TNF-α induced cell death is mainly transduced through TNF-RI and the 
signaling pathway is similar to Fas induced apoptosis (Schulze-Osthoff et al., 
1998). 
There have been several reports describing the modulation of Fas- or 
TNF-RI-mediated apoptosis by GSH. According to these reports, acute GSH 
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depletion induced insensitivity to death receptor stimulation (Hentze et al., 
1999; Hentze et al., 2000), while, during prolonged GSH depletion increased 
death receptor mediated apoptosis was observed (Chiba et al., 1996; Colell et al., 
1998; Xu et al., 1998). The reports strongly indicated that Nrf2 activity may 
influence the sensitivity of death signaling, but the relationship between Nrf2 
and apoptotic signaling was not clearly characterized. Recently, Kotlo et al. 
demonstrated that inactivation of Nrf2 by antisense or by using a membrane 
permeable dominant-negative polypeptide sensitized cells while conversely, 
overexpression of Nrf2 protected cells from Fas-induced apoptosis. In addition, 
they demonstrated that N-acetyl L-cysteine (NAC), a precursor to GSH, 
protected cells from Fas-mediated killing in HeLa cells (Kotlo et al., 2003).  
In this report, we have analyzed the sensitivity of death signaling (Fas and 
TNF-α-mediated apoptosis) in Nrf2 deficient mice and demonstrated a high 
susceptibility to death signals in vivo. Pre-administration of glutathione ethyl 
monoester (GSH-OEt), which up-regulates GSH, canceled the observed 
enhanced sensitivity.  This indicates that the low intracellular GSH levels 
which resulted from Nrf2 deficiency is a primary cause for the susceptibility. 
To investigate the role of Nrf2 in Fas-mediated apoptosis, cultured Nrf2 
deficient thymocytes were examined in the presence of an agonistic anti-Fas 
antibody. Our results showed that a deficiency in Nrf2 increased the percentage 
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of apoptotic thymocytes following Fas stimulation (Figure 1A). Anti-Fas 
antibody, at a  concentration of 1 μg/ml, induced 60% of cell death in 
thymocytes from Nrf2 deficient mice while, using the same treatment, 40% of 
cells from wild type mice died (P <0.05). Recently, it has been found that 
prolonged GSH depletion enhances Fas-mediated apoptosis (Haouzi et al., 2001). 
We and others reported that intracellular GSH levels were reduced in Nrf2 
deficient cells (Chan and Kwong, 2000; Ishii et al., 2000). Therefore, we 
suspected that the observed sensitivity of cultured thymocytes to Fas-mediated 
apoptosis could be due to a depletion of cellular GSH levels resulting from a 
deficiency in Nrf2. Administration of GSH-OEt can increase the intracellular 
GSH concentration in vitro and in vivo (Rahman et al., 2001; Chen et al., 2001). 
Therefore, we examined the effect of GSH-OEt treatment on Fas-mediated 
apoptosis in Nrf2 deficient thymocytes. The addition of GSH-OEt to Nrf2 
deficient thymocytes re-established the sensitivity of Fas-mediated apoptosis to 
the level of wild type mice thymocytes (Figure 1B). These results suggest that 
the enhanced sensitivity of the Fas signal in Nrf2 deficient thymocytes was due 
to a decrease in the intracellular GSH levels. However, due to the complicated 
nature of the GSH system, it is not possible to exclude the possibility that the 
administered GSH affected the adequate induction of some alternative adaptor 
molecule(s), whose function could be to prevent Fas-mediate apoptosis. To 
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confirm the hypothesis that the enhanced sensitivity of the Fas signal was due 
to a decrease in the intracellular GSH levels, we analyzed mice chronically 
treated with buthionine sulfoximine (BSO). BSO is a specific GSH synthesis 
inhibitor that when administered to mice serves as a model of chronic GSH 
depletion (Sanjay et al., 2000). Wild type mice were given water supplemented 
with BSO (400 mg/kg/day) for 6 weeks. After 6weeks, thymocytes were 
isolated from BSO treated and control (untreated) wild type mice. Analyzes 
showed that Fas stimulation resulted in a larger percentage of apoptotic cells 
among BSO treated thymocytes compared to wild type control (Figure 1C). 
Furthermore, the addition of GSH-OEt to BSO treated thymocytes 
re-established the sensitivity of Fas-mediated apoptosis to the level of BSO 
untreated mice thymocytes (Figure 1D). These results support the hypothesis 
that chronic GSH depletion enhances Fas-mediated apoptosis in vitro. 
In the same experiment we also determined the intracellular levels of 
GSH of the thymocytes (Figure 1E). The GSH level of Nrf2 deficient thymocytes 
was decreased to almost the same level as that of BSO treated wild type 
thymocytes. GSH-OEt addition increased the GSH levels of Nrf2 deficient and 
BSO treated thymocytes to the same level as that of Nrf2 wild type thymocytes. 
These results also support the hypothesis that chronic GSH depletion enhanced 
Fas-mediated apoptosis in vitro.  
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 It is well known that the administration of anti-Fas antibody to mice can 
induce fulminant hepatitis as a result of Fas-mediated apoptosis (Ogasawara et 
al., 1993). The effect of hepatocellular apoptosis in vivo triggered by anti-Fas 
antibody in Nrf2 deficient mice was examined. Anti-Fas antibody (Jo-2, 
2μg/mouse) was administered intraperitoneally to Nrf2 deficient and wild type 
mice. Serum alanine aminotransferase (ALT) activities were determined as 
indices of hepatotoxicity. Serum ALT activity after Fas stimulation was 
significantly increased in Nrf2 deficient mice compared to Nrf2 wild type mice 
(P<0.05) (Table 1). At 12 hours after anti-Fas antibody administration, ALT 
activity in sera from Nrf2 deficient mice had increased to over 10000 IU/l, while 
those of wild type mice was around 5000 IU/l. Three out of five Nrf2 deficient 
mice were already dead at eight hour after injection. To prove the enhancement 
of hepatitis in Nrf2 deficient mice was also due to a decrease in intracellular 
GSH levels, GSH-OEt was administrated before anti-Fas antibody injection. The 
addition of GSH-OEt blocked the enhancement of Fas induced fulminant 
hepatitis suggesting that a low level of intracellular GSH might be the cause of 
the enhancement. To confirm this theory, we investigated the effect of 
chronically treating the mice with BSO. Serum ALT activity after Fas 
stimulation was significantly increased in BSO treated wild type mice 
compared to untreated wild type mice (P<0.05) (Table 1). The addition of 
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GSH-OEt cancelled the enhancement of Fas induced fulminant hepatitis in BSO 
treated mice. These results suggest that a low level of intracellular GSH could 
be the cause of the enhancement in vivo. 
 Fas and TNF-RI share homology at their cytoplasmic death domain, a 
region necessary for apoptotic signaling (Schulze-Osthoff et al., 1998). 
D-galactosamine (GalN) is well known to increase the susceptibility of mice to 
hepatotoxicity and the lethal effects of TNF-α. Therefore, the effect of TNF-α on 
hepatocellular apoptosis in GalN sensitized Nrf2 deficient mice was examined. 
TNF-α (0.5μg/mice) was administered intraperitoneally to GalN sensitized 
Nrf2 deficient and wild type mice. The result showed that serum ALT activity 
after TNF-α administration was significantly increased in Nrf2 deficient mice 
compared to wild type mice. The mean ALT activity in the sera from Nrf2 
deficient mice was 8732 ± 4413 IU/l at 12 hour after induction (Table 2). On the 
other hand, the ALT activity of wild type mice was less than 2000 IU/l when 
taken at the same time point. This represents a four-fold difference of ALT 
activity between these two groups. GSH-OEt addition decreased the ALT 
activity in Nrf2 deficient mice to almost the same level as that of wild type mice. 
To investigate the influence of GSH depletion, we examined wild type mice 
chronically treated with BSO. Serum ALT activity after TNF-α  stimulation was 
significantly increased in BSO treated wild type mice compared to untreated 
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wild type mice (P<0.05) (Table 2). The addition of GSH-OEt decreased the 
enhancement of TNF-α  induced fulminant hepatitis in BSO treated wild type 
mice. This result suggested that a low level of intracellular GSH would be the 
cause of the enhanced TNF-α−mediated apoptosis. 
Histopathological examination revealed that the number of apoptotic 
hepatocytes was increased in Nrf2 deficient mice compared to wild type mice 
(Figure 2). Massive hepatocyte apoptosis, as judged by the frequent appearance 
of nuclear fragmentation and a hyperchromatic nuclear membrane was 
observed in Nrf2 deficient mice (Figure 2B). Further major pathological signs 
included diffuse congestive hemorrhagic foci (Figure 2B). In contrast, liver 
specimens from a comparable area taken from mice injected with GSH-OEt 
before TNF-α administration showed a morphology (Figure 2C) that was 
indiscernible from that of wild type mice (Figure 2A). BSO treated wild type 
mice revealed massive hepatocyte apoptosis by TNF-α administration as well as 
Nrf2 deficient mice (Figure 2D). The administration of GSH-OEt to BSO treated 
wild type mice re-established the sensitivity of TNF-α-mediated apoptosis to 
the level of wild type mice as judged by histological appearance (data not 
shown). The histological analyses also support that Nrf2 deficiency enhances 
the sensitivity of TNF-α-mediated apoptosis as a consequence of GSH 
depletion. 
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To confirm the effect of GSH on TNF-α mediated apoptosis in vivo, we 
determined the total liver GSH levels (Figure 2E). Mice were sacrificed 4 hours 
after TNF-α and GalN administration. Livers were homogenized and total GSH 
levels were measured. The GSH level of Nrf2 deficient livers was decreased to 
almost the same level as that of BSO treated wild type livers. GSH-OEt addition 
increased the GSH levels of Nrf2 deficient and BSO treated wild type livers to 
almost the same level as that of Nrf2 wild type livers. These results suggest that 
chronic GSH depletion can enhance TNF-α-mediated apoptosis in vivo.  
An accumulating number of reports describe the relationship between 
Nrf2 and various kinds of stresses. Cho and colleagues reported that Nrf2 had a 
key protective role during hyperoxic lung injury (Cho et al., 2002). Enomoto et 
al. and Chan et al. clearly demonstrated an enhanced susceptibility to 
acetaminophen in Nrf2 deficient mice (Enomoto et al., 2001; Chan et al., 2001). 
We also reported that Nrf2 female mice developed autoimmune 
glomerulonephritis probably due to a susceptibility to oxidative stress (Yoh et 
al., 2001). In addition, Ramos-Gomez et al. showed that Nrf2 was central to the 
constitutive and inducible expression of phase two enzymes in vivo and 
dramatically influences susceptibility to carcinogens (Ramos-Gomez et al., 2001). 
However few studies has been reported the relationship between Nrf2 and 
apoptosis. This study is the first report describing Nrf2 regulates the sensitivity 
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of death receptor signals through intra-cellular glutathione levels in vivo. The 
inhibiton of death signal is a novel role of Nrf2. Possibly, the observed 
enhancement in death signals caused by a deficiency in Nrf2 is a safety 
mechanism to eliminate cells which have accumulated damage as a 
consequence of an inadequate stress response. Further analyses must be 
performed to explore the relationship between apoptotic regulation by Nrf2 
and various stresses including diseases.  
 
Acknowledgments 
 
This work was supported in part by Grants-in-Aid from the Ministry of 
Education, Science, Sports and Culture, the Japanese Society for Promotion of 
Sciences (RFTF), Core Research for Evolutional Sciences and Technology 
(CREST), and Program for Promotion of Basic Research Activities for 
Innovative Biosciences (PROBRAIN). We thank Vincent Kelly (Banyu 
Pharmaceutical Co., Ltd.), for their help and discussion and N. Kaneko 
(University of Tsukuba) for their excellent assistance.
 15
References 
 
Anderson M. (1997). Adv. Pharmacol., 38, 65-78. 
Chan JY and Kwong M. (2000). Biochim. Biophys. Acta., 1517, 19-26. 
Chan K, Han XD and Kan YW. (2001). Proc. Natl. Acad. Sci. USA, 98, 4611-4616. 
Chen TS, Richie JP, Nagasawa HT and Lang CA. Mech. Ageing. Dev., (2001).  
120, 127-139. 
Chiba T, Takahashi S, Sato N, Ishii S and Kikuchi K. (1996). Eur. J. Immunol., 26, 
1164-1169. 
Cho HY, Jedlicka AE, Reddy SP, Kensler TW, Yamamoto M, Zhang LY and 
Kleeberger SR. (2002). Am. J. Respir. Cell Mol. Biol., 26, 175-182. 
Colell A, Garcia-Ruiz C, Miranda M, Ardite E, Mari M, Morales A, Corrales F, 
Kaplowitz N and Fernandez-Checa JC. (1998). Gastroenterology, 115, 
1541-1551. 
Droge W, Schulze-Osthoff K, Mihm S, Galter D, Schenk H, Eck HP, Roth S and 
Gmunder H. (1994). FASEB J., 8, 1131-1138. 
Enomoto A, Itoh K, Nagayoshi E, Haruta J, Kimura T, O'Connor T, Harada T 
and Yamamoto M. (2001). Toxicol. Sci., 59, 169-177. 
Favreau LV and Pickett CB. (1991). J. Biol. Chem., 266, 4556-4561. 
Galle PR, Hofmann WJ, Walczak H, Schaller H, Otto G, Stremmel W, Krammer 
 16
PH and Runkel L. (1995). J. Eep. Med., 182, 1223-1230. 
Hall AG. (1999). Eur. J. Clin. Invest., 29, 238-245. 
Haouzi D, Lekehal M, Tinel M, Vadrot N, Caussanel L, Letteron P, Moreau A, 
Feldmann G, Fau D and Pessayre D. (2001). Hepatology, 33, 1181-1188. 
Hentze H, Kunstle G, Volbracht C, Ertel W and Wendel A. (1999). Hepatology, 30, 
177-185. 
Hentze H, Gantner F, Kolb SA and Wendel A. (2000). Am. J. Pathol., 156, 
2045-2056. 
Hirata H, Takahashi A, Kobayashi S, Yonehara S, Sawai H, Okazaki T, 
Yamamoto K and Sasada M. (1998). J. Exp. Med., 187, 587-600. 
Ishii T, Itoh K, Takahashi S, Sato H, Yanagawa T, Katoh Y, Bannai S and 
Yamamoto M. (2000). J. Biol. Chem., 275, 16023-16029. 
Itoh K, Igarashi K, Hayashi N, Nishizawa M and Yamamoto M. (1995). Mol. Cell. 
Biol., 15, 4184-4193. 
Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, Yamamoto M and 
Nabeshima Y. (1997). Biochem. Biophys. Res. Commun., 236, 313-322. 
Itoh K, Ishii T, Wakabayashi N and Yamamoto M. (1999). Free Radic. Res., 31, 
319-324. 
Jones TW, Thor H and Orrenius S. (1986). Arch. Toxicol. Suppl., 9, 259-271. 
Kotlo KU, Yehiely F, Efimova E, Harasty H, Hesabi B, Shchors K, Einat P, Rozen 
 17
A, Berent E and  Deiss LP. (2003). Oncogene, 22, 797-806. 
Leist M, Gantner F, Kunstle G, Bohlinger I, Tiegs G, Bluethmann H and Wendel 
A. (1996). Mol. Med., 2, 109-124. 
Medema JP, Scaffidi C, Kischkel FC, Shevchenko A, Mann M, Krammer PH and 
Peter ME. (1997). EMBO J., 16, 2794-2804. 
Meister A. (1992). Biochem. Pharmacol., 44, 1905-1915. 
Moi P, Chan K, Asunis I, Cao A and Kan YW. (1994). Proc. Natl. Acad. Sci. USA, 
91, 9926-9930. 
Nagata S. (1997). Cell, 88, 355-365 
Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, 
Kitamura Y, Itoh N, Suda T and Nagata S. (1993). Nature, 364, 806-809. 
Prestera T, Talalay P, Alam J, Ahn YI, Lee PJ and Choi AM. (1995). Mol. Med., 1, 
827-837. 
Rahman I, Mulier B, Gilmour PS, Watchorn T, Donaldson K, Jeffery PK and 
MacNee W. (2001). Biochem. Pharmacol., 62, 787-794. 
Ramos-Gomez M, Kwak MK, Dolan PM, Itoh K, Yamamoto M, Talalay P and 
Kensler TW. (2001). Proc. Natl. Acad. Sci. USA, 98, 3410-3415. 
Rushmore TH, King G, Paulson KE and Pickett CB. (1990). Proc. Natl. Acad. Sci. 
USA, 87, 3826-3830.  
Sanjay KS, Hong X, Ajai P, Xun H, Jianxia G and Shivendra V. (2000). Cancer 
 18
 19
Lett., 153, 35-39. 
Schulze-Osthoff K, Ferrari D, Los M, Wesselborg S and Peter ME. (1998). Eur. J. 
Biochem., 254, 439-459. 
Thronberry NA and Lazebnik Y. (1998). Science, 281, 1312-1316. 
Uhlig S. and Wendel A. (1992). Life Sci., 51, 1083-1094. 
Widmann C, Gibson S and Johnson GL. (1998). J. Biol. Chem., 273, 7141-7147. 
Xu Y, Jones BE, Neufeld DS and Czaja MJ. (1998). Gastroenterology, 115, 
1229-1237. 
Yoh K, Itoh K, Enomoto A, Hirayama A, Yamaguchi N, Kobayashi M, Morito N, 
Koyama A, Yamamoto M and Takahashi S. (2001). Kidney Int., 60, 
1343-1353. 
Zhivotovsky B, Burgess DH, Vanags D M and Orrenius S. (1997). Biochem. 
Biophys. Res. Commun., 230, 481-488.
Table 1 
 
Hepatotoxicity and lethality in Nrf2 deficient mice induced by anti-Fas 
antibody 
  ALT (IU/l) Survival rate (survived/all) 
Treatment Time (h) Nrf2 deficient wild type 
BSO treated  
wild type 
Nrf2 
deficient wild type 
BSO treated  
wild type 
GSH-OEt(-) anti-Fas 0 42±9 35±8 37±4  5/5   5/5   5/5  
GSH-OEt(-) anti-Fas 4 1301±329* 626±100 1273±240 *  5/5   5/5   5/5  
GSH-OEt(-) anti-Fas 8 8110±2101* 3560±1175 8642±2346*  3/5   5/5   5/5  
GSH-OEt(-) anti-Fas 12 12566±4848* 4582±835 9739±4342*  3/5   4/5   4/5  
GSH-OEt(+) anti-Fas 0 26±10 32±8 25±9  5/5   5/5   5/5  
GSH-OEt(+) anti-Fas 4 671±106 431±96 398±119  5/5   5/5   5/5  
GSH-OEt(+) anti-Fas 8 2621±766 1832±805 2798±468  5/5   5/5   5/5  
GSH-OEt(+) anti-Fas 12 4944±563 3456±934 4878±889  5/5   5/5   5/5  
Anti-Fas antibody (Jo-2, 2μg/mouse) was administered intraperitoneally as a 
mixture in 0.2 ml of pyrogen-free saline to 12-week-old Nrf2 deficient and wild 
type (BSO treated and untreated) mice. At 0, 4, 8 and 12 h after injection, blood 
was collected and serum ALT activities were determined as indices of 
hepatotoxicity using an automated analyzer (DRY-CHEM 3500; Fuji Film). 
GSH-OEt (20mg/mouse) was injected intravenously 2 h before anti-Fas 
antibody injection to increase the intracellular GSH level. Results are expressed 
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as mean ± SD for 3 to 5 mice. Survival rate indicates number of survived/all 
mice. (*) Significantly different from wild type (BSO untreated) mice (P<0.05). 
 
Table 2 
 
Hepatotoxicity and lethal effect in Nrf2 deficient and BSO treated mice induced 
by TNF- α 
  ALT (IU/l) Survival rate (survived/all) 
Treatment Time (h) Nrf2 deficient wild type 
BSO treated  
wild type 
Nrf2 
deficient wild type 
BSO treated 
wild type 
GSH-OEt(-) TNF-α 0 31±8 41±8 42±4  5/5   5/5   5/5  
GSH-OEt(-) TNF-α 4 942±301 * 235±104 873±276 *  5/5   5/5   5/5  
GSH-OEt(-) TNF-α 8 8207±1431* 1642±815 5642±2142*  4/5  5/5   4/5 
GSH-OEt(-) TNF-α 12 8732±4413* 1901±1403 6739±3732*  3/5   4/5   4/5  
GSH-OEt(+) TNF-α 0 25±9 37±11 33±7  5/5   5/5   5/5  
GSH-OEt(+) TNF-α 4 363±182 212±84 375±130  5/5   5/5   5/5  
GSH-OEt(+) TNF-α 8 1837±765 898±562 1098±501  5/5   5/5   5/5  
GSH-OEt(+) TNF-α 12 2247±1989 1267±1217 2878±842  5/5   5/5   5/5  
 
TNF-α (0.5μg) (obtained from BD Bioscience) was administered 
intraperitoneally as a mixture in 0.2 ml of pyrogen-free saline to 12-week-old 
Nrf2 deficient and wild type (BSO treated and untreated) mice. 
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D-galactosamine hydrochloride (GalN) (obtained from Nacalai Tesque) was 
pre-injected intravenously to increase the susceptibility of mice to 
hepatotoxicity 30 min before TNF-α injection. GSH-OEt (20mg/mouse) was 
injected intravenously 2 h before TNF-α injection to assess the importance of 
the intracellular GSH level. 0, 4, 8 and 12 h after injection, blood was collected 
and serum ALT activities were determined. Results are shown as mean ± SD for 
3 to 5 mice. Survival rate indicates number of survived/all mice. (*) 
significantly different from wild type mice (P < 0.05). 
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 Figure 1 
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 Effects of Nrf2 deficiency on cultured thymocytes treated with an agonistic 
anti-Fas antibody. The generation of Nrf2 deficient mice was previously 
described (Itoh et al., 1997). The present study utilized 12-week-old mice from 
the same litters with an ICR background. Freshly isolated thymocytes from 
Nrf2 deficient, chronically treated with BSO (6 weeks) and untreated wild type 
mice were incubated overnight with the indicated concentrations of anti-Fas 
antibody. The cells were washed with DMEM supplemented with 10% 
heat-inactivated fetal bovine serum, 0.5 mM 2-mercaptoethanol, 2 mM 
glutamine, 1 mM HEPES (pH 7.4) and antibiotics (all from Invitrogen). The cells 
were again washed in medium before use in subsequent tissue culture 
experiments. The cells (1×106 /ml) were incubated with various concentrations 
of anti-Fas antibody (Jo-2, BD Bioscience) for 12 hours. Cell viability was 
determined by trypan blue exclusion. The cells were pre-incubated with 
GSH-OEt (obtained from WAKO) (2mM for 15-20 min) to increase the 
intracellular pool of GSH. Each Bar represents the mean ± SD. (A) Survival rate 
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of Nrf2 deficient thymocytes after Fas stimulation was significantly decreased 
(P < 0.05) compared with wild type thymocytes. Nrf2 deficiency increased the 
percentage of apoptotic thymocytes after Fas stimulation. (*) indicates 
significant difference from wild type thymocytes (P < 0.05). (B) GSH-OEt 
protected Nrf2 deficient thymocytes against Fas-mediated apoptosis. 
Thymocytes were pre-incubated with 2mM GSH-OEt. There was no significant 
difference in the survival rate between Nrf2 deficient and wild type thymocytes 
with 2mM GSH-OEt. (C) The survival of wild type thymocytes chronically 
treated with BSO was significantly decreased after Fas stimulation (P < 0.05) 
compared with untreated wild type thymocytes. BSO, a specific GSH synthesis 
inhibitory agent, increased the percentage of apoptotic thymocytes after Fas 
stimulation, similar to Nrf2 deficiency.  (**) indicates significant difference 
from BSO untreated wild type thymocytes (P < 0.05). (D) GSH-OEt protected 
BSO chronically treated thymocytes against Fas-mediated apoptosis. There was 
no significant difference in the survival rate between BSO treated and untreated 
wild type thymocytes with 2mM GSH-OEt. (E) GSH levels of thymocytes were 
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examined pre and post anti-Fas antibody administration. GSH levels were 
measured using a Total Glutathione Quantification Kit (DOJINDO). The GSH 
levels of Nrf2 deficient thymocytes were significantly reduced compared to 
wild type thymocytes, being decreased to almost the same level as that of BSO 
treated thymocytes. GSH-OEt addition increased the GSH levels of Nrf2 
deficient and BSO treated thymocytes to almost the same level as that of Nrf2 
wild type thymocytes. (#) indicates significantly difference from untreated wild 
type thymocytes (P < 0.05). 
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Figure 2 
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Nrf2 deficiency enhanced TNF-αmediated apoptosis and GSH-OEt rescued 
Nrf2 deficient mice from TNF-α-mediated apoptosis. Mice were sacrificed 12 
hours after TNF-α (0.5μg) injection. GalN was pre-injected intravenously 30 min 
before TNF-α injection. GSH-OEt (20mg) was injected 2 hours before 
TNF-α administration to increase intracellular glutathione levels. The liver was 
excised, fixed with 10% buffered formalin, sectioned at a thickness of 5m, and 
stained with hematoxyline and eosin for light microscopic examination. (A) 
Liver section of wild type mouse: a few apoptotic hepatocytes exhibit apoptotic 
nuclei. (B) Nrf2 deficient mouse: numerous apoptotic hepatocytes were 
observed (Arrows indicate apoptotic nuclei). (C) Nrf2 deficient mouse with 
GSH-OEt administration: apoptotic cells were decreased by the addition of 
GSH-OEt. (D) BSO treated wild type mouse: numerous apoptotic hepatocytes 
were observed as seen in Nrf2 deficient mouse (Arrows also indicate apoptotic 
nuclei). (E) GSH levels of livers were examined pre and post 
TNF-α administration. Total GSH level was measured in homogenized liver 
samples. The GSH level of Nrf2 deficient livers was significantly reduced 
 28
 29
compared to wild type being decreased to almost the same level as that of BSO 
treated livers. GSH-OEt addition increased the GSH levels of Nrf2 deficient and 
BSO treated livers to almost the same level as that of Nrf2 wild type liver. (*) 
indicates significantly difference from untreated wild type livers (P < 0.05). 
